🔗 Share this article

Given that the US continues making historic revisions to its vaccine recommendations, one figure appears in a surprising turn: Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines during the pandemic and has concentrated on alleged fatalities after Covid vaccination in her short position at the FDA.

Planned Changes to Pediatric Immunization Program

Health officials were set to announce major revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of step with a large portion of the world with little proof for improved outcomes. This reveal has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is scheduled to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment might represent a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending some pediatric shot schedules in the US to become more like Denmark's approach, a country with universal health coverage and a population roughly the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – typically the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Background

The appointee has little discernible experience in pharmaceutical research, oversight or management, which has been customary for previous leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in industry regulation.”

Former commissioners of the center would “understand regulatory frameworks and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who ran CBER have had.”

CDER has an vast portfolio at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office authorizes thousands of generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and each of these need to be managed,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a significant leadership component to the role, which oversees in excess of 5,000 staff members. “It is a enormous management job, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Initiatives

Regarding concerns about Høeg’s qualifications and whether this selection indicates greater collaboration among agency officials on immunizations, a spokesperson stated that the “concerns are based on incorrect presumptions”.

“Her experience is consistent with the functions of her job,” the official stated, pointing to the months Høeg spent advising the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's recently launched expedited review system, a contentious one-day medication authorization process that allegedly troubled her predecessors. “How are these therapies being picked for this fast-track system? Who makes the decisions?” Howard asked. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards less stringent rules of pharmaceuticals, aside from shots.”

Established Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She released a analysis using unverified volunteer-provided data to estimate the rate of myocarditis following COVID-19 vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership included altering regulations for new vaccines and halting “unnecessary” vaccines, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of excluding young men from getting COVID-19 vaccines.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to fit the evidence in a extremely misleading, dishonest manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|